Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Drugs + Chemotherapy in Newly Diagnosed T-ALL
NCT07203352Phase 3Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of dasatinib, sorafenib in T-cell acute lymphoblastic leukemia (T-ALL), sponsored by Nanfang Hospital, Southern Medical University. Started Oct 2025; status: recruiting.
02
Drugs
dasatinibsorafenib
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07203352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203352.